Liyan Zhuang, MD
Urology · Boston, MANPI 1578728200
Payments from drug & device makers
Across 150 payments — averaging $48.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Scientific Affairs, LLC$2K
- Teleflex LLC$837
- Uromedica, Incorporated$830
- Astellas Pharma US Inc$705
- Medtronic$540
- Johnson & Johnson$461
- plus $2K from 28 others
What the payments were for
- Consulting fees$1,51521%
- Travel & lodging$1,18416%
- Food & beverage$4,42461%
- Education$1462%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Scientific Affairs, LLC | 2 | $1,515 |
| Teleflex LLC | 7 | $837 |
| Uromedica, Incorporated | 3 | $830 |
| Astellas Pharma US Inc | 28 | $705 |
| Medtronic(2 entities) | 13 | $540 |
| Johnson & Johnson | 16 | $461 |
| AbbVie(2 entities) | 9 | $261 |
| Endo Pharmaceuticals Inc. | 11 | $216 |
| Urogen Pharma, Inc. | 4 | $210 |
| Pfizer | 11 | $175 |
| Angiodynamics, Inc. | 1 | $166 |
| Procept Biorobotics Corporation | 1 | $163 |
| 180 Medical, Inc. | 6 | $159 |
| Boston Scientific | 5 | $114 |
| Antares Pharma, Inc. | 2 | $112 |
| Endo USA, Inc. | 4 | $103 |
| Myovant Sciences Inc. | 1 | $91 |
| Blue Earth Diagnostics | 3 | $73 |
| Coloplast | 3 | $54 |
| Urovant Sciences Inc | 3 | $52 |
| Ferring Pharmaceuticals Inc. | 2 | $50 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $45 |
| Convatec Inc. | 1 | $45 |
| Axonics, Inc. | 1 | $40 |
| Tolmar Pharmaceuticals, Inc. | 2 | $38 |
| Immunitybio, Inc. | 1 | $32 |
| Agiliti Surgical, Inc. | 1 | $31 |
| Progenics Pharmaceuticals, Inc. | 1 | $29 |
| Tempus AI, Inc | 1 | $26 |
| Telix Pharmaceuticals | 1 | $24 |
| Metuchen Pharmaceuticals | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Rochester Medical Corporation | 1 | $19 |
| Myriad Genetic Laboratories, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Erleada$1,515
- ProACT$703
- UroLift$481
- Nanoknife$166
- AquaBeam Robotic System$163
- ZUSDURI$118
- UroLift System$112
How this compares
$7,269 in reported general payments places this provider in the 75th percentile of 327 urology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 141 | $80,619 |
| GemtesaVibegron | 88 | $67,506 |
| Mirabegron ErMirabegron | 11 | $3,822 |
| Tamsulosin Hcl | 227 | $3,260 |
| Trospium Chloride ErTrospium Chloride | 11 | $2,221 |
| Finasteride | 96 | $1,450 |
| Testosterone | 20 | $1,331 |
| Oxybutynin Chloride | 59 | $1,195 |
| Solifenacin Succinate | 12 | $1,154 |
| Estradiol | 12 | $1,130 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 16 | $367 |
| Sildenafil Citrate | 13 | $97 |
| CefuroximeCefuroxime Axetil | 11 | $60 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 14 | $47 |
| Methocarbamol | 12 | $17 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $705 | $80,619141 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $19 | $67,50688 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 327 urology providers in Massachusetts.
Other urology in Boston
- Christopher CutieBoston$3.5M
- Brian EisnerBoston$1.4M
- Mark PrestonBoston$1.2M
- Alejandro SanchezBoston$349K
- Adam KibelBoston$316K
- Tony LuongoBoston$303K
- Stephen DretlerBoston$298K
- Adam FeldmanBoston$232K
- Mehrdad AlemozaffarBoston$214K
- Andrew WagnerBoston$126K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.